<DOC>
	<DOCNO>NCT02098343</DOCNO>
	<brief_summary>The purpose study make preliminary assessment efficacy combine APR-246 carboplatin/PLD chemotherapy regimen , compare carboplatin/PLD chemotherapy regimen alone , patient platinum sensitive recurrent high grade serous ovarian cancer ( HGSOC ) mutate p53 . In addition , study aim ass safety profile combine APR-246 carboplatin/PLD chemotherapy regimen compare carboplatin/PLD chemotherapy regimen alone , evaluate potential biomarkers , assess biological activity tumor surrogate tissue . The trial enroll maximum 400 patient .</brief_summary>
	<brief_title>p53 Suppressor Activation Recurrent High Grade Serous Ovarian Cancer , Phase Ib/II Study Systemic Carboplatin Combination Chemotherapy With Without APR-246</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Confirmed High Grade Serous Ovarian Cancer , positive nuclear immunohistochemical ( IHC ) stain p53 Disease Progression 624 month first second platinum base regimen At least single measurable lesion . Phase II patient Adequate organ function prior registration Toxicities previous cancer therapy must recover grade 1 ( defined Common Terminology Criteria Adverse Events [ CTCAE ] 4.0 ) Chronic stable grade 2 peripheral neuropathy secondary neurotoxicity prior therapy may consider case case basis ECOG performance status 0 1 Prior exposure cumulative dos doxorubicin &gt; 400 mg/m2 epirubicin &gt; 720 mg/m2 History allergic reaction carboplatin , platinum contain compound mannitol and/or hypersensitivity PLD excipients Unable undergo image either CT scan MRI Evidence medical condition ( psychiatric illness , infectious disease , neurological condition , physical examination laboratory finding ) may interfere plan treatment , affect patient compliance place patient high risk treatment related complication Concurrent malignancy require therapy ( exclude noninvasive carcinoma carcinoma situ ) Is take concurrent ( within 4 week prior registration ) chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( i.e. , use nonapproved indication ( ) context research investigation ) . Supportive care measure allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Ovarian carcinoma</keyword>
	<keyword>High Grade Serous Ovarian Cancer</keyword>
	<keyword>Recurrent Cancer</keyword>
	<keyword>Resistant Cancer</keyword>
</DOC>